Drug listing recommendations from health technology assessment (HTA) agencies often fail to coincide with one another. We conducted a comparative analysis of listing recommendations in Australia (PBAC), the Netherlands (CVZ), Sweden (TLV) and the UK (NICE) over time, examined interagency agreement, and explored how process-related factors-including time delay between HTA evaluations, therapeutic indication and orphan drug status, measure of health economic value, and comparator-impacted decision-making in drug coverage. Agreement was poor to moderate across HTA agency listing recommendations, yet it increased as the delay between HTA agency appraisals decreased, when orphan drugs were assessed, and when low-value medicines (immunosuppressants, antineoplastics) were removed from the sample. International differences in drug listing recommendations seem to occur in part due to inconsistencies in how the supporting evidence informs assessment, but also to differences in how domestic priorities shape the value-based decision-making process.
INTRODUCTION
Health technology assessment (HTA) is frequently used to inform value-based decision-making.
Since it involves systematically evaluating health economic evidence, HTA is supported by a growing number of digital resources and regulatory initiatives that promote the sharing of clinical data. In the US, for instance, all applicable clinical trials must submit results to the publicly searchable registry clinicaltrials.gov,(1) making submitted data available for use by international appraisers. Regulators, including England's National Institute for Health and Care Excellence (NICE), may also require manufacturers to submit all clinical data within the company's possession anywhere in the world prior to drug review. (2) Evidence from recent comparative studies indicates that a similar set of clinical trials are in fact made available to drug appraisals, (3, 4) which might lead one to anticipate significant overlap in value-based decision-making on drug coverage around the world.
Contrary to this expectation, a growing body of literature has found that the HTA-based decisions on whether to recommend public reimbursement of new medicines rarely coincide with one another. (5, 6) The literature has generally examined this issue from the perspective of the last available listing recommendation, and has suggested that international differences are accounted by social determinants, including preferences for treatment, disease severity and rarity (7, 8) and local clinical practice;(4) as well as methodological factors, including HTA design and sufficiency of pharmacoeconomic evidence, (7, 9) and use of comparative data.(4) As has been previously argued, however, HTA is a complex process that cannot be fully understood if the perspective concentrates exclusively on final listing decisions.(10) Rather, social and methodological factors may impact final listing decisions, but only to the extent that they influence complex HTA processes that occur over time.
These complex processes are reflected in HTA agency listing recommendations, which may evolve as time passes. Periodic reassessment of cost-effectiveness may be mandated, (11) but it may also result from an appeal against initial opinions on listing, (12, 13) ad hoc reassessment initiated by the emergence of new health economic evidence, (14) or risk-sharing agreements. (2) In England, for instance, public guidance may be reviewed and re-issued if there is significant new evidence that is likely to change opinions on drug listing.(2) Australian listing recommendations can also be deferred for further review or appealed on 'procedural' or 'merit-based' grounds. Sponsors are also allowed an unlimited number of resubmissions should new information become available, and can request an independent review of negative recommendations. (15) Australian authorities in fact highlight that a decision not to recommend or change listing status "does not represent a final … view about the merits of the medicine", but rather contributes to an "improved understanding of the listing process". (16) Therefore, to better understand the causes of disagreement in HTA-based decision-making, we conducted a comparative analysis of drug listing recommendations emerging over time from Australia, England, the Netherlands, and Sweden. Within this framework, we examined interagency agreement in drug listing, and how social and methodological factors pertaining to the assessment process-including therapeutic indication and orphan drug status, time delay between HTA evaluations, health economic value, and comparator-influenced listing recommendations. This analysis found that international differences in drug listing recommendations exist in part due to inconsistencies in how the supporting evidence informs assessment, but also to differences in how domestic priorities shape the value-based decision-making process.
METHODOLOGY

Inclusion Parameters
This study examined HTA review processes and drug listing decisions from four HTA agencies in Australia (PBAC), England (NICE), the Netherlands (CVZ; 'Zorginstituut Nederland' since 2014), and Sweden (TLV) between 2009 -2013. These were selected as leading examples of agencies that make similar use of HTA to inform value-based decision-making in drug coverage (Table 1) . The five-year period Jan 2009 -Dec 2013 was chosen in order to pragmatically optimize the size of our sample while also capturing contemporary HTA practice.
Data Extraction
HTA Appraisal Documents
A stepwise approach was used to identify all drugs that were appraised by the four HTA agencies.
This process first identified all unique molecules that were assessed by NICE between 2009 -2013 (n=102). Of these, reviews for 67 drugs were publicly available as of July 2014 from the PBAC, of which 56 were also found to have been appraised by the CVZ. Of those 56 drugs, the TLV was found to have assessed 43 through July 2014. Since appraisals were publicly available for those 43 drugs from Australian, Dutch, Swedish, and UK HTA agencies, they were used as a common sampling frame in this study. Drug name, indications, listing recommendations, year of assessment, incremental cost-effectiveness ratios (ICERs), and review comparators were then extracted from all appraisal documents corresponding to each of the 43 drugs. If multiple HTA evaluations existed for drugindication pairs, data was extracted from both the first and last appraisal that had been published 
Analysis
Two analytical endpoints were included within the main analyses: an assessment of the distribution of listing recommendations across the four national HTA agencies, and inter-country agreement in listing decisions. Both endpoints were further stratified across potential drivers of international discrepancies in drug listing recommendations.
Listing Recommendations and HTA Agency Associations
HTA agency listing rates were calculated by dividing the number of drug-indication pairs given an 'L' or 'LWR' recommendation by the total number of drug-indication pairs evaluated in each country.
Pearson's χ 2 test for independence and odds ratios were used to test for, and measure the strength of, association between listing recommendations and issuing HTA agency. Correspondence analysis was used to visually examine the association between first and last available listing recommendations and issuing HTA agency in low-dimensional space. (20) 
Agreement in the Overall and Stratified Sample
Agreement in drug-indication pair listing recommendations from the four HTA agencies was measured using Cohen's kappa coefficients. These were categorized into different levels of agreement using previously established thresholds. (21) Building on the available literature on factors that may explain levels of agreement in listing recommendations, these were stratified by: ATC groupings for treatment indications and orphan drug status; time delay (years) between assessments from NICE and the other HTA agencies, categorized as ≤3 years, ≤2 years, ≤1 year, 0 years; and agreement in ICER and selection of comparator. This allowed us to consider the impact of social factors (preferences for treatment, disease severity and rarity) and methodological factors (evidence or pricing developments, health technology assessment) on the process of HTA-based decision-making.
Listing Recommendations and Assessments of Value
Finally, this analysis examined the association between final available listing recommendations and ICERs, a health economic measure of value. This analysis included all drug-indication pairs for which ICER estimates were given in terms of cost per QALY gained. The bound to one-sided directional ICER estimates and ICER range midpoints were used if discrete ICER values were not reported. Any drug-indication pair that was found to be dominated by its comparator was excluded. Table 1 summarizes the policy context related to health technology assessment and drug listing in Australia, the Netherlands, Sweden, and the UK. Though there is much overlap in the overall review process used by all four HTA agencies, there are differences in how health economic evidence is used, and in the factors that are considered during appraisal.
RESULTS
In sum, all four countries provide public guidance for health technology evaluations, and most rely primarily on manufacturer-submitted health economic analyses. NICE reviews manufacturersubmitted health economic evidence, as other agencies do, but it also works with Technology Assessment Groups (TAGs) to independently assess the value from treatment. NICE is also the only HTA agency to use explicit willingness-to-pay thresholds when determining whether to recommend treatment coverage through the National Health Service. Although the CVZ does not apply a "hard limit" to willingness-to-pay thresholds, it does operate within a suggested "bandwidth". All countries nevertheless claim that they consider severity of disease, health needs, and availability of alternative 
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The null hypothesis of independence between HTA agency and listing recommendations was rejected for both the first and last available appraisals (First: χ 2 = 74.94; p < 0.01; Last: χ 2 = 54.66; p < 0.01).
Local odds ratios were therefore used to measure the association between HTA agencies and initial and final available listing recommendations ( Table 2 ). The TLV and CVZ were most likely to issue positive listing recommendations; negative listing recommendations from the PBAC frequently became positive with time; and NICE was, generally speaking, most restrictive in the positive listing recommendations that it issued.
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These results were consistent with correspondence analysis (eFigure 2). The principal dimension in correspondence analysis biplots for first and last available assessments appeared to consistently highlight opposition in listing recommendations. However, while this appeared to initially represent opposition between positive (L) and negative (DNL/D) outcomes, opposition appeared to better reflect a choice between listing with or without restrictions in last available assessments. In settings where listing recommendations can change over time, this may suggest that HTA agencies generally become more accommodative and transition from considering 'whether or not to list' to 'whether or not to list with restrictions'.
The association between HTA agency and listing rates however varied by drug indication. To draw inference, we limited our analysis to ATC subgroups with a sample size of at least 5 drug-indication pairs (antithrombotics, antineoplastics, and immunosuppressants). For each HTA agency, immunosuppressants were associated with a final listing rate that exceeded that of the entire sample (Figure 2) . Apart from the CVZ, a similar phenomenon was observed for antithrombotic agents. In contrast, antineoplastics had a lower listing rate than the overall institutional average for NICE, PBAC and the TLV; the CVZ's listing rate for antineoplastics was above the agency's average (Figure 2) .
Please see the appendix for more information on all remaining indications (eFigure 3).
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Agreement in the Overall and Stratified Sample
Consistent with previous findings, there was poor to fair agreement in listing recommendations across all agency to agency pairings (Table 3) . NICE listing recommendations most often agreed with those from the PBAC, while the lowest level of agreement was observed between PBAC and TLV listing recommendations. The overall level of agreement in listing outcomes generally increased as the delay between agency assessments decreased and when orphan drugs were assessed. Inter-rater agreement was lower for antineoplastics and immunosuppressants than that observed for the entire sample (Table 3) . Removing L01-(antineoplastics) and L04-indicated (immunosuppressants) drug products tended to increase the overall level of agreement between listing recommendations from NICE and the PBAC, TLV, and CVZ (eTable 1). Agreement in listing recommendations also generally decreased between first and last available assessment, and there was poor to fair agreement in listing recommendations across the other factors that were considered (Table 3 ). 
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Listing Recommendations and Assessments of Value
[INSERT FIGURE 3]
Although the PBAC, TLV and CVZ less frequently published ICER data, there appeared to be a similar, albeit generally weaker, relationship between drug listing recommendations and ICER observations where data existed (eFigure 4-6). In light of earlier findings, these data suggest that NICE and the PBAC are less likely than the TLV and CVZ to recommend funding of medicines that are deemed to provide low value, many of which are indicated for cancer.
DISCUSSION
HTA-Based Practices in Drug Listing
All 
Convergence in Drug Listing Recommendations
This analysis found poor to modest agreement in the listing recommendations that were issued by Australian, Dutch, Swedish, and English HTA agencies. The overall level of agreement was highest for listing recommendations from Australia and the UK, and lowest for those issued by Australian and Swedish HTA agencies. Agreement also tended to decrease between first and last available listing recommendations. Since it has focused on the latter, this finding may suggest that the available literature underestimates the level of agreement in drug listing recommendations from HTA agencies, particularly for the period soon after initial market entry.
To also examine how the available evidence, social and institutional preferences, and processes for health economic assessment are associated with agreement in drug listing recommendations, this study stratified its sample by the delay occurring between health technology assessments, therapeutic indication and orphan status, and agreement in ICERs and health economic comparators.
Increasing the delay between HTA evaluations was associated with a decrease in the level of agreement between listing recommendations from NICE and the PBAC and TLV. This finding may suggest that HTA agencies differ in how they incorporate new evidence, and that this can in turn impact agreement across their respective listing recommendations. Agreement also tended to increase when the sample was limited to orphan medications, particularly for listing recommendations from NICE and the TLV and CVZ. These findings may suggest that common health needs and preferences can have a converging effect on drug listing recommendations.
Within our sample, the divergence observed across all international drug listing recommendations was driven by disagreement on listing recommendations for L01-(antineoplastics) and L04-(immunosuppressants) indicated drug products. Considered alongside the finding that antineoplastics and immunosuppressants are also often associated with comparatively low levels of assessed health economic value, these findings may suggest that considerations of value-for-money strongly influence drug listing decisions-particularly in the UK and Australia-and that they are an important source of discrepancy in international listing recommendations.
Health economic evaluations are an important component to technological assessments. To examine how these influence listing decisions across countries, we evaluated the association between drug listing recommendations and a health economic measure of value, the incremental cost effectiveness ratio (ICER). 40-60% of commonly evaluated drug-indication pairs that provided ICER estimates received similar ICER assessments across agency pairings, though the proportion of ICERs in agreement generally decreased between first and last available assessment. Methodological differences in how value is assessed may therefore partly account for drug listing discrepanciesperhaps particularly in final listing recommendations-though the extent to which this is true varies by setting. This, however, reaffirms our earlier findings suggesting that methodological features of health economic assessments are not the only cause of international disagreement in whether to publicly reimburse medicines. Any influence on international agreement in listing recommendations from features of HTA appears to be compounded by differences in institutional priorities, insofar as how they shape the regulatory process and value-based decision-making. To gauge the appropriateness of differences in listing recommendations, additional work is therefore needed to examine how institutional priorities and practices reflect societal needs and preferences for treatment.
CONCLUSION
Consensus in global HTA has become an important health policy objective, as it represents an opportunity to both reduce duplication of regulatory effort and improve transparent, value-based decision-making in drug coverage. To better understand the causes of disagreement in HTA-based recommendations on whether to include medicines on publicly reimbursable drug lists, this study conducted a comparative analysis of drug listing recommendations emerging over time from Australia, the Netherlands, Sweden, and the UK. Although final drug listing rates in these countries are generally high, they vary considerably across settings and tend to increase over time in Australia and the UK. Still, there is poor to moderate agreement in the drug listing recommendations from these four highly-developed health systems, though this is associated with the time delay between health technology assessment, orphan drug status, and with medicinal classes that are deemed to provide low value-for-money (immunosuppressants, antineoplastics). Poor to moderate agreement in listing decisions is also compounded by HTA-based value assessments that rarely coincide with one another.
International differences in drug listing recommendations therefore seem in part due to early inconsistencies in how the supporting evidence informs appraisal, but also to differences in how domestic priorities shape the regulatory process and value-based decision-making. Moving forward, additional work is needed to examine how well drug review processes and outcomes reflect social values regarding the trade-off between publicly subsidized drug coverage and use of resources. Final available incremental cost effectiveness ratios (ICER) for NICE drug-indication pairs, by ATC group (x-axis), listing recommendation, and sorted by ATC group average ICER (USD/QALY). Sample includes all drug-indications pairs for which ICERs were available. Where ATC group has >1 observation, 95%CI are provided around group average ICER. All values presented in constant 2013 USD.
EXHIBITS
